AD/A-002 793

CLINICAL STUDIES ON THE PATHOPHYSIOLOGY OF BUBONIC AND PNEUMONIC PLAGUE: SOME OBSERVATIONS OF TYPHOID FEVER

Nguyen Dinh Tiep

Cho-Quan Hospital

Prepared for:

Army Research and Development Group (Far East)

25 November 1974

DISTRIBUTED BY:

National Technical Information Service U. S. DEPARTMENT OF COMMERCE

CURITY CLASSIFICATION OF THIS PAGE (WITH	I DIOT	READ INSTRUCTIONS
REPORT DOCUMENTAT	ION PAGE	BEFORE COMPLETING FORM
REPORT NUMBER FE-507-2	2. GOVT ACCESSION NO.	AD/A-002793
TITLE (and Subtilie)		5. TYPE OF REPORT & PERIOD COVERED
CLINICAL STUDIES ON THE PATHO	PHYSIOLOGY OF	Annual Report
BUBONIC AND PNEUMONIC PLAGUE;	SOME OBSERVATIONS	15 Feb 73 - 14 Feb 74
OF TYPHOID FEVER (U)		6. PERFORMING ORG. REPORT NUMBER
		FE-JU/-2
AUTHOR(.)		B. CONTRACT ON GRANT NOMELING
Nguyen Dinh Tiep		DA-RDRF-S92-544-73-G197
THE CONTRACT OF CANES AND AD	DRESS	10. PROGRAM ELEMENT, PROJECT, TASK
(how)wan Hospital		
Saigen Republic of Vietnam		2N061102B71D 00 154FE
Sargon, Republic of Victorian	,	
CONTROLLING OFFICE NAME AND ADDRES	S	12. REPORT DATE
ILS. Army R&D Group (Far East)	25 November 1974
APO San Francisco 96343		13. NUMBER OF PAGES
		24
4. MONITORING AGENCY NAME & ADDRESS(II	different from Controlling Office)	15. SECURITY CLASS. (or this report)
		Unclassified
Same as Block 11		15. DECLASSIFICATION/DOWNGRADING SCHEDULE
Approved for public release;	distribution unlimit	rom Report)
Approved for public release; 7. DISTRIBUTION STATEMENT (of the abstract	distribution unlimit	rom Report)
6. DISTRIBUTION STATEMENT (of this Report) Approved for public release; 17. DISTRIBUTION STATEMENT (of the abstract 18. SUPPLEMENTARY NOTES	distribution unlimit entered in Block 20, it different t	irom Report)
 6. DISTRIBUTION STATEMENT (of this Report) Approved for public release; 17. DISTRIBUTION STATEMENT (of the abstract 18. SUPPLEMENTARY NOTES 19. KEY WORDS (Continue on reverse side if nec Bubonic plague South Vietnau Endemic area 	distribution unlimit entered in Block 20, it different t essary and identify by block numb M	ted. from Report)
6. DISTRIBUTION STATEMENT (of this Report) Approved for public release; 17. DISTRIBUTION STATEMENT (of the abstract 18. SUPPLEMENTARY NOTES 19. KEY WORDS (Continue on reverse side if nec Bubonic plague South Vietnau Endemic area Salmonella typhi	distribution unlimit entered in Block 20, if different f essary and identify by block numb	rem Report)
Approved for public release; Approved for public release; 7. DISTRIBUTION STATEMENT (of the abstract 19. KEY WORDS (Continue on reverse side if nec Bubonic plague South Vietnau Endemic area Salmonella typhi Infection	distribution unlimit entered in Block 20, if different f essary and identify by block numb M	rom Report)
6. DISTRIBUTION STATEMENT (of this Report) Approved for public release; 17. DISTRIBUTION STATEMENT (of the abstract 18. SUPPLEMENTARY NOTES 19. KEY WORDS (Continue on reverse side if nec Bubonic plague South Vietnau Endemic area Salmonella typhi Infection Drugs	distribution unlimit entered in Block 20, if different f essary and identify by block numb m	rom Report) er)
 Approved for public release; Approved for public release; DISTRIBUTION STATEMENT (of the abstract) DISTRIBUTION STATEMENT (of the abstract) SUPPLEMENTARY NOTES SUPPLEMENTARY NOTES SUPPLEMENTARY NOTES Subonic plague South Vietnal Endemic area Salmonella typhi Infection Drugs ABSTRACT (Continue on reverse elde II nec In 22 Vietnamese patients to diagnosed by positive cultur except one isolated from the drugs tested, including trim dia, hypotension, and leukoc receiving streptomycin, chlo binations of these drugs. I 	distribution unlimit entered in Block 20, if different f essary and identify by block numb m essary and identify by block numb with fever and bubo, e or serologic response patients were susc ethoprim. Common cli ytosis. One patient ramphenicol, trimetho ntravascular coagulo	er) <u>Yersinia pestis</u> infection wa nse. All strains of Y. pesti ceptible to most antimicrobia inical fertures were tachycar died; the others survived wh oprim-sulfamethoxazole, or co pathy was demonstrated in 19 (Cont)
 Approved for public release; Approved for public release; DISTRIBUTION STATEMENT (of the abstract) DISTRIBUTION STATEMENT (of the abstract) SUPPLEMENTARY NOTES SUPPLEMENTARY NOTES SUPPLEMENTARY NOTES SUPPLEMENTARY NOTES SUPPLEMENTARY NOTES Subonic plague South Vietnal Endemic area Salmonella typhi Infection Drugs ABSTRACT (Continue on reverse side if nec In 22 Vietnamese patients to diagnosed by positive culture except one isolated from the drugs tested, including trim dia, hypotension, and leukoc receiving streptomycin, chlo binations of these drugs. I 	distribution unlimit entered in Block 20, if different i essary and identify by block numb m essary and identify by block numb with fever and bubo, e or serologic respor se patients were susc ethoprim. Common cli ytosis. One patient ramphenicol, trimetho ntravascular coagulo	er) Yersinia pestis infection wa nse. All strains of Y. pesti ceptible to most antimicrobia inical fertures were tachycar died; the others survived wh oprim-sulfamethoxazole, or co pathy was demonstrated in 19 (Cont)

- A.Y **

Unclassified

SECURITY CLASSIFICATION OF THIS PAGE(Witen Date Entered)

patients who had elevated titers of fibrinogen-fibrin degradation products in serum; these titers decreased during convalescence. At the time of discharge, peripheral blood smears of most patients showed eosinophilia.

Blood cultures from febrile patients in Saigon yielded Salacheila typhi in eight cases. Four isolates were sensitive to all antibiotics and four isolates were highly resistant to chloramphenicol, tetracycline, streptomycin, and sulphadiazine. While receiving chloramphenicol the patients with drug-resistant S. typhi had prolonged febrile courses, and one patient died. The multiple drug resistance was associated with three distinct Vi-phage types and could be transferred from three of the isolates to recipient Escherichia coli organisms. (Author)

10

Unclassified SECURITY CLASSIFICATION OF THIS PAGE(When Data Entered)



DDC DISTRIBUTION AND AVAILABILITY NOTICE

Approved for public release; distribution unlimited.

DISPOSITION INSTRUCTIONS

Destroy this report when it is no longer needed. Do not return it to the originator.

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.

行

ABSTRACT

In 22 Vietnamese patients with fever and bubo, <u>Yersinia pestis</u> infection was diagnosed by positive culture or serologic response. All strains of <u>Y</u>. <u>pestis</u> except one isolated from these patients were susceptible to most antimicrobial drugs tested, including trimethoprim. Common clinical features were tachycardia, hypotension, and leukocytosis. One patient died; the others survived while receiving streptomycin, chloramphenicol, trimethoprim-sulfamethoxazole, or combinations of these drugs. Intravascular coagulopathy was demonstrated in 19 patients who had elevated titers of fibrinogen-fibrin degradation products in serum; these titers decreased during convalescence. At the time of discharge, peripheral blood smears of most patients showed eosinophilia.

Blood cultures from febrile patients in Saigon yielded <u>Salmonella</u> <u>typhi</u> in eight cases. Four isolates were sensitive to all antibiotics and four isolates were highly resistant to chloramphenicol, tetracycline, streptomycin, and sulphadiazine. While receiving chloramphenicol the patients with drug-resistant <u>S</u>. <u>typhi</u> had prolonged febrile courses, and one patient died. The multiple drug resistance was associated with three distinct Vi-phage types and could be transferred from three of the isolates to recipient <u>Escherichia coli</u> organisms.

TABLE OF CONTENTS

Page

I.	Introduction1-2
II.	Antimicrobial Susceptibilities of Y. pestis Isolates2
III.	Blood Coagulation Studies in Plague2-3
IV.	Complement Levels in Plague
v.	Eosinophilia in Convalescent Plague
VI.	Blood Coagulation Studies in Typhoid Fever
VII.	Antibiotic Resistance in Typhoid Fever
VIII.	Conclusions
IX.	Appendices
	A - Table I. 9-10 B - Table II. 11 C - Table III. 12 D - Table IV. 13 E - Table V. 14 F - Figure I. 15
x.	Literature Cited16-17
XI.	Publications

C

0

INTRODUCTION

I.

0

Throughout history great epidemics of bubonic and pneumonic plague have ravaged many areas of the world and have claimed millions of victims. About 40 per cent of Europe's population succumbed during the Middle Ages and more recently between 1910 and 1930 about 10 million died in India (1). Although most areas of the world today are free of plague, Vietnam yearly reports thousands of cases; in 1970 there were 4,045 cases confirmed and 77 deaths (1).

Whether the low incidence of plague outside Vietnam is due to eradication campaigns and improved sanitation or due to natural biologic cycles is not known. Certainly the potential for new epidemics exists in many less developed countries. Similarly travelers to endemic areas such as Vietnam may carry incubating disease to distant countries and start a new epidemic.

Relatively little is known about the pathophysiology of human plague because this disease occurs largely in areas of the world remote from modern laboratories. The hypothesis that plague exotoxin, which depresses mitochondrial respiration in mouse infections (2), is clinically important as a cardiotoxin has not been supported by studies in patients. There is mounting evidence that plague endotoxin is responsible for purpuric skin lesions and intravascular coagulation observed in a few patients (3,4), but additional clinical data is needed to support this hypothesis.

Although bacterial toxins from Yersinia pestis have been identified the relative importance of their roles in mediating clinical events in man has not been determined. Plague exotoxin produces electrocardiographic changes in susceptible laboratory animals and inhibits mitochondrial enzymes (2). However, tissue levels required for these effects are higher than usually obtained in experimental infection. Thus, it appears unlikely that this toxin is important to man. The role of endotoxin in plague is more certain. Y. pestis possesses an endotoxin that is physiologically and chemically similar to endotoxins found in other Gram-negative bacteria (5,6). The human equivalent of the generalized Shwartzman reaction has been observed in plague patients at autopsy (3) and a clinical study in Vietnam has reported purpura and intravascular coagulation (4). Whether these lesions are attributable to circulating endotoxin and whether fibrin split products are present require answers obtainable by available laboratory assays. More knowledge of toxin mechanisms of tissue damage in plague snould lead to improvements in therapy. Although available antibiotics are effective in plague, some patients have such advanced infection that they die despite antibiotic treatment. In such patients new approaches such as antagonists to biochemical effects of plague toxins will be required.

Another Gram-negative bacillus, <u>Salmonella typhi</u>, which causes typhoid fever, is also endemic in Saigon and is responsible for many hospitalizations and deaths annually in Saigon. Although there have been recent reports of antibiotic-resistant <u>S. typhi</u> in Vietnam, chloramphenicol has remained the treatment of choice. Therefore, bacterial isolates were tested for antibiotic sensitivity.

II. Antimicrobial Susceptibilities of Y. pestis Isolates.

Cultures were initially identified as Y. pestis at the Pasteur Institute in Saigon by colonial morphology, gram stain and microscopic morphology, and lysis by bacteriophage. Cultures of 15 patients were successfully transported on Cary-Blair media and reisolated in Baltimore. These 15 isolates were confirmed as Y. pestis by characteristic biochemical reactions and by phage lysis. From patient no. 17 the bubo culture yielded two distinct colony types: a mucoid colony and a smaller dry colony type typical of Y. pestis.

Isolates from all 15 patients (except the mucoid colony type of patient no. 17) were susceptible (by the Kirby-Bauer method) to ampicillin, cephalothin, chloramphenicol, furadantin, gentamicin, kanamycin, streptomycin, and tetracycline. All isolates were resistant to colymycin. The mucoid colony type of patient no. 17 was resistant to ampicillin, furadantin, and kanamycin; although the colony was susceptible to all other drugs tested, the zones of inhibition around all disks were considerably smaller than for the other isolates.

Eleven of these isolates were tested by the agar dilution method for susceptibility to trimethoprim and sulfamethoxazole. For seven isolates the MIC of trimethoprim was 1 μ g/ml, while for three isolates the MIC was 3 μ g/ml. The mucoid colony type of patient no. 17 was resistant to 3 μ g of trimethoprim/ml. The MIC for sulfamethoxazole was 30 μ g/ml for all isolates except one (patient no. 20), for which it was 100 μ g/ml. Combinations of the drugs (one part trimethoprim to 20 farts sulfamethoxazole by weight) resulted in MICs of 0.1 μ g of trimethoprim/ml and 2 μ g of sulfamethoxazole/ml for all isolates except the mucoid colony type of patient no. 17, which had MICs of 0.3 μ g of trimethoprim/ml and 6 μ g of sulfamethoxazole/ml.

III.

Blood Coagulation Studies in Plague.

Twenty-six patients were studied and are summarized in Table I. The first 21 patients were either bacteriologically proven or had diagnostic Fraction I antibody rises. The remaining 5 patients were suspected of having plague because of the clinical presentation. Platelets were measured by direct counting in a hemacytometer (normal range 150,000-300,000 per mm³). Fibrinogen levels were assayed by a modification of the thrombin time (normal range 250-400 mg per 100 ml) (7). Fibrinogen degradation products were detected by the tanned red cell hemagglutination inhibition immunoassay (TRCHII) (8).

The TRCHII assay is the most specific test available for disseminated intravascular coagulation (DIC), and a titer of 8 or greater is considered elevated. By this criterion 20 patients had DIC on admission and 12 patients in convalescence. Platelet counts and fibrinogen levels proved to be less sensitive indicators of DIC and were decreased on admission in only 9 and 6 patients respectively as shown in Table I. Despite this high incidence of abnormal coagulation tests, none of the patients showed overt evidence for a bleeding tendency.

IV.

Complement Levels in Plague.

Serum levels of hemolytic complement (C-3) were measured by microtiter assay at Cordis Laboratories, Miami, Florida. Reference sera were run simultaneously with our samples to approximate a normal range; these were in the range 3840-5120 CH50 units per ml.

In 11 patients with proven plague infection, Table II shows that 10 had lower levels than the normal range on admission to the hospital. In 2 patients, including one who died the following day, complement levels were undetectably low. During convalescence, sera was available in 8 patients for re-examination of complement. All were lower than normal. In 5 patients complement levels declined from admission values, while in 3 patients levels were observed to increase or remain unchanged from admission values.

v.

Eosinophilia in Convalescent Plague.

The white blood count in acute plague infection is usually elevated in the range of 20,000 per mm³ with a preponderance of neutrophilic leukocytes often including juveniles and metamyelocytes. Eosinophils are rarely present in acute plague. However, no one has previously remarked upon the differential white cell counts in convalescing patients.

A. J. v ...

Table III compares admission and convalescent eosinophil counts in 17 patients with plague in whom convalescent blood smears were obtained. The eosinophil counts were estimated by multiplying the per cent eosinophils by the total white blood cell counts. Absolute eosinophil counts greater than 300 per mm³ are usually regarded as abnormal. Using this value, only 4 of 17 patients on admission had eosinophilia, while during convalescence 14 of 17 had eosinophilia.

VI.

Blood Coagulation Studies in Typhoid Fever.

During the course of our plague studies in Saigon, it was intended that other febrile illnesses be studied concomitantly to provide control information on other Vietnamese patients. At Cho-Quan Hospital, Ward 11-C, where patients with plague were admitted, typhoid fever was so commonly seen that separate observations on these patients seemed appropriate.

Table IV summarizes the clinical features of 11 patients. Unlike the patients with plague, the hemorrhagic phenomena of melena, purpura, rose spots, or epistaxis were present in most cases. Two of the patients died with significant gastro-intestinal bleeding. Significant titers of fibrinogen degradation products were present in all but 2 of the patients on admission. During convalescence titers remained elevated in most patients. Platelet counts and fibrinogen levels were commonly decreased as shown in Table IV.

VII.

Antibiotic Resistance in Typhoid Fever.

Vietnamese physicians have been aware of chloramphenicol-resistant typhoid fever for about 2 years. This awareness is based on treatment failures in patients and on antibiotic sensitivity testing of isolated bacteria. At Cho-Quan Hospital we also observed some patients who failed to respond to chloramphenicol. Two illustrative cases are described:

A. This 16-year old boy began having fever and vomiting 3 weeks before admission. One week before admission he noted the onset of watery diarrhea several times a day and his continuing fever was accompanied by chills and sweating. One day before admission he developed abdominal pain. The temperature was 105°F, pulse 120 per

- 1.10

minute, respirations 28 per minute, blood pressure 115/75 mm Hg. He had mild, diffuse abdominal tenderness. The spleen was palpable 3 cm below the left costal margin. A macular blanching erythematous rash was present on his anterior trunk and abdomen. The hematocrit was 47%, white blood cell count 4300 per cu mm, and platelets 150,000 per cu mm. A blood culture yielded <u>S. typhi</u>. Initial therapy was intravenous fluids and chloramphenicol 500 mg orally 3 times a day. His hospital course and therapy are summarized in Figure I. Bactrim^R (trimethoprim 80 mg, sulfamethoxazole 400 mg) tablets 4 times a day was started on the fourteenth day. He was discharged afebrile on the twenty-first day.

B. Ten days before admission this 15 year old boy developed fever accompanied by watery diarrhea about 4 times a day. Two days before admission he began taking chloramphenicol 750 mg a day. On the day of admission he became delirious and passed a dark red stool. The temperature was 104°F, pulse 152 per minute, respirations 48 per minute, and BP 85/60 mm Hg. He was disoriented and combative. The sclerae were lightly icteric and the liver palpable 6 cm below the right costal margin. The hematocrit was 32°, white blood cell count 4900 per cu mm, and platelets 176,000 per cu mm. A blood culture yielded S. typhi. Lumbar puncture revealed clear fluid under normal pressure with no white blood cells; the culture was negative. He was treated with intravenous chloramphenicol 3 gm per day and intermittent doses of hydrocortisone 100 mg without improvement. On the fifth day the temperature was 102°F; he was stuporous and passed melenic stools. At this time the serum urea nitrogen was 92 mg per 100 ml, creatinine 3.3 mg per 100 ml, bilirubin 1.4 mg per 100 ml (Direct 1.2) SGOT 610 milli-international units (M-IU) per ml, SGPT 56 M-IU per 100 ml, and alkaline phosphatase 66 M-IU per 100 ml. He was transfused but became comatose and died on the sixth hospital day.

From 8 patients blood cultures yielded <u>S. typhi</u>. By the Kirby-Bauer method at the NCDC, Atlanta, Georgia 4 of the isolates were found to be resistant to chlormaphenicol, tetracycline, streptomycin, and sulfadiazine. Table V shows the results of tube-dilution sensitivity testing, phage-typing, and mating studies for transfer of antibiotic resistance (R-factors) to <u>E. coli</u>. The 4 resistant strains were comprised of 3 distinct Vi-phage types. Three of the resistant strains transferred a full resistance pattern to recipient <u>E. coli</u> strains.

VIII.

CONCLUSIONS

Previous studies had shown that disseminated intravascular coagulation (DIC) could occur in plague infections (3,4). These studies emphasized the generalized Shwartzman phenomenon as evidenced by renal glomerular thrombi at autopsy (3) and skin biopsies of purpura showing fibrin thrombi (4). However, blood studies for DIC had previously included only platelets, fibrinogens, partial thromboplastin times, and ethanol gelation tests (4), all of which may be abnormal in situations other than DIC. The availability of the highly specific TRCHII for fibrinogen-fibrin degradation products and the elevated titers frequently found in this study allows us to conclude that DIC is commonly present in acute plague despite the rarity of clinical evidence for hemorrhagic diathesis.

Serum complement levels were found reduced in most patients studied. However, the significance of these reductions is hard to judge at this time because of the small numbers of patients studied and the lack of controls in normal Vietnamese subjects. In other acute bacterial infections serum complement levels have been noted to be rarely reduced (9), but studies of Gram-negative sepsis showed a mean complement level lower than normal (10), and another study of bacterial shock showed lower levels in shock than in normotensive infected patients (11).

Eosinophilia was frequently seen in these convalescing plague patients but was rare during the acute stage. Without knowledge of their eosinophil counts prior to infection, it is not possible to know whether during convalescence patients re-acquired eosinophilia or develop it <u>de novo</u> as a result of the plague infection and its treatment. Experimental studies in eosinophilic animals show that acute pyelonephritis with <u>E. coli</u> will abolish eosinophilia (12); eosinopenia likewise could be produced by injections of typhoid vaccine, which contains endotoxin. In our patients a similar mechanism may have occurred. It is also possible that plague infection or antibiotic treatment provoked migration of intestinal helminths, either by the stress of fever or disturbance of normal bowel flora by antibiotics.

Patients with typhoid fever in this study had a high incidence of DIC based on low platelet counts and high titers of fibrinogen-fibrin degradation products. It is interesting to speculate what role DIC played in their bleeding syndromes. The clinical severity and therapeutic failures with chloramphenicol in this series of patients is similar to the experience with drug-resistant typhoid fever in Mexico (13). Although the prevalence of drug-resistance in Vietnam may not be so high as that suggested in our small sample because of selection bias due to outpatient treatment failures, another report from Saigon showed a similarly high frequency of drug resistance in 11 of 35 isolates of <u>S</u>. typhi (14). Thus, drug-resistant typhoid fever appears to be common in Saigon. Because typhoid fever may be fatal before antibiotic sensitivities are available, chloramphenicol should not be used alone in initial therapy. Ampicillin has been shown as effective alternative drug, (15) and trimethoprim-sulfamethoxazole has been reported as highly effective (16). It is recommended that enteric fever in Vietnam or in travelers recently in Vietnam be initially treated with chloramphenicol combined with ampicillin or trimethoprimsulfamethoxazole until sensitivity results are available. If an isolate of <u>S. typhi</u> in a particular patient is susceptible to chloramphenicol, then chloramphenicol should be used alone (17).

Epidemiological data on seasonal occurrence and vehicles of transmission are not available. Hospital records and local medical opinion suggest that enteric fever is endemic throughout Vietnam without apparent seasonal variation or identifiable common-source outbreaks. Chloramphenicol-resistant typhoid fever was first reported in Vietnam in 1972, and has been attributed to the indiscriminant use of chloramphenicol (14). However, widespread dispensing of chloramphenicol by pharmacies and physicians has occurred over a much longer period of time, and perhaps other explanations for the appearance of drug resistance meed to be sought. The four resistant strains encountered in this study were all highly resistant to tetracycline, streptomycin, and sulphadiazine as well as to chloramphenicol. Three of these four strains transferred their resistance to all four antibiotics to recipient E. coli organisms, and it is suspected that the fourth strain, in which transfer was not demonstrated, contained the identical R factor without a mobilizing transfer factor. This pattern of R-factor-mediated resistance is thus different from S. typhi strains from Chile and Aden reported resistant only to chloramphenicol and non-transferable, and from S. typhi from Kuwait which transferred resistance to chloramphenicol, tetracycline, and ampicillin (18). On the other hand, the strains from the 1972 Mexican typhoid epidemic had the same four-drug resistance pattern as those in this report, and all were R-factor mediated (18).

Ĉ

It is significant that among the four S. typhi strains in this report, all with seemingly identical R factors, there were three distinct Vi-phage typing patterns. Phage-typing data are available for only some of the previously reported chloramphenicol-resistant S. typhi. Two strains from Chile were Vi-phage types A and 46; two strains from Kuwait in 1967 were also Vi-phage type A, and a third was Vi-phage type El (18). The three phage types of our resistant strains differed from these; furthermore, the degraded Vi strain is readily distinguishable from the degraded Vi strain of the Mexican epidemic of 1972. In contrast to the situation in Mexico in 1972, our resistant S. typhi strains may represent evidence for the epidemic spread of an R factor rather than of its bacterial hosts, which are already endemic in Vietnam. The same may have been true in Kuwait in 1967 when identical R factors were found in S. typhi strains belonging to two distinct Vi-phage types. Similar multiple drug-resistance episomes have been demonstrated in Shigella dysenteriae 1 from the Central American

pandemic, 2 <u>S</u>. <u>flexneri</u> 2a strains from outbreaks in the United States, as well as in the epidemic <u>S</u>. <u>typhi</u> strains from Mexico (19-21).

The emergence of R-factor-mediated drug resistance in <u>S</u>. <u>typhi</u> in Vietnam presents an opportunity for studding the epidemiology of antibiotic resistance. Whether the same R factor is present in other bacterial species and whether this R factor exists in other parts of the country where chloramphenicol usage is less common remain unknown.

(

APPENDIX A

(Part I)

0

0

Table I. Clinical and Coagulation Data in Plague

		Sex	Temperature Rectal °F	Blood Pressure mm Hg	White Blood Cell Count per mm ³
Patient No.	UBC				22 600
		ţ.	1049	92/60	000 77
-4		. >	104	1	11,400
7	77	2 3	1052	85/65	22,300
ę	4	×	COT	80/60	20,700
4	13	(H4	-103-	00/00 06/50	24.800
	ŝ	W .	1048	05/00	8.500
	39	W	1000	00/06	005 11
-		X	1007	00/06	
		: >	104	120/65	14,200
80	10	1 >	1022	50/20	25,400
6	æ	2		100/65	. 35,000
10	50	E :	201	100/60	16,400
11	46	W	OOT.		22.000
15	15	M	102	00/00	44 600
1 1	67	(Fr	103	0//06	23 100
	12	X	1024	80/60	
t 1 1	27	M	104	09/05	
2	,	: >	104	80/60	12,900
16	S	2		100/50	20,400
17	6	¥	TC4	70/50	22,600
18	40	M	1040		13.100
61	17	X	1050	76/40	8, 800
20	45	£4	104	06/001	10.000
10	57	£4	1024	OD / DOT	5 400
1 4	57	X	100	09/06	
77		2	80F	01/06	007°7T
23	DT I	2 7	1035	105/75	6,600
24	10	2 : I	002	120/90	10,200
25	49	¥ ∑	1018	112/80	11,000
071	TO	:			

• 9

(Part II)

.

-71" •

•••••

2

.

APPENDEX A

(

0

Table I. Clinical and Cossulation Data in Plague

Attent Fibrinogen Fibrinogen Platelets No. per mm ³ mg per 100 ml Products, Titer Platelets 1 364,000 135 8 - - 2 190,000 3135 8 - - 3 2222,000 365 16 574,000 4 298,000 365 16 574,000 5 301,000 355 16 274,000 7 785 16 274,000 274,000 8 200 32 242,000 274,000 9 200,000 270 128 - - 114,000 310 8 274,000 274,000 11 175,000 32 166,000 274,000 11 152,000 274,000 8 174,000 11 152,000 32 166,000 166,000 128 200,000 274,000 132 174,000		
Attent Fibrinogen per um ³ Fibrinogen ger um ³ Fibrinogen per um ³ Patelets 1 364,000 135 8 - - 2 199,000 360 135 8 - - 2 199,000 360 16 745,000 540 64 574,000 3 2222,000 310 8 - - - 3 201,000 250 16 574,000 - - 3 201,000 310 16 274,000 - - - 3 114,000 310 16 274,000 - - - 11 1/52,000 32 16 574,000 - - - 11 1/52,000 32 128 - - - - 11 1/52,000 32 256 000 -		Filedana
No. per mm ³ ag per 100 ml Products, Titer per mm ³ 1 364,000 135 8 - - 2 190,000 540 64 574,000 - - 3 2298,000 540 64 574,000 - - - 4 298,000 540 64 574,000 -	Fibrinogen	Degradation
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	mg per 100 ml	Products, Titer
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Died	,
3222,000285165301,000540645301,0005406114,00085778,0003108310859200,0002709200,0002701082,0003211152,000321274,0003101314,00031014174,0003201514432162703217174,00030018174,00032016284,00032017155,00032016284,00030017155,00032018174,00019198,00030019198,00030019198,00030017155,0003216284,00030017155,0003216284,00030017155,0003216284,00030017155,00032174,00019017156,00018156,00019198,00019198,0001919819190191901919019190191901919019190191901919019190 </td <td>N/A</td> <td>ı</td>	N/A	ı
4 298,000 540 64 574,000 7 786,000 310 32 242,000 8 301,000 85 16 274,000 9 200,000 310 8 274,000 11 198,000 270 32 242,000 11 152,000 310 8 274,000 11 152,000 370 32 346 12 14,000 300 32 366,000 12 14,000 320 32 366,000 13 14,000 320 32 366,000 14 178,000 320 32 366,000 15 64,000 300 270 32 366,000 16 178,000 300 270 32 366,000 16 178,000 300 270 32 310,000 16 284,000 300 2 270,000 310,000 17 178,000 32 256 270,000 310,000 17	170	80
5 $301,000$ 250 322 $486,000$ 778,0008516274,0008198,0002708274,0009200,000270321281082,00032032366,00011152,00032032366,00012827032366,00011152,0003408134,0001274,00030032134,0001364,000105256270,00014284,00030027032174,00015155,000300266270,00016284,000300266174,00017155,0003008174,00017155,00032174,00018178,00032174,00017155,00032174,00018175,00032174,0001992,0003404250,0001992,0003404250,0001992,0003404250,0001992,0003404250,0001992,0003404250,0001992,0003404250,0001992,0003404250,0001992,0003404250,0001992,0003404250,0001992,0003404250,000 <tr< td=""><td>340</td><td>32</td></tr<>	340	32
7 78,000 85 16 242,000 8 198,000 310 8 242,000 9 200,000 310 8 242,000 10 82,000 310 8 244,000 11 152,000 320 32 36,000 12 82,000 300 32 36,000 11 152,000 300 32 36,000 12 82,000 300 32 36,000 13 64,000 300 32 134,000 14 178,000 32 134,000 32 15 284,000 32 270,000 32 15 198,000 140 32 270,000 15 198,000 300 32 270,000 15 198,000 340 4 250,000 19 198,000 340 4 250,000 19 190 8 310,000 32 19 190 8 310,000 32 310,000	145	16
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	66	00
778,0003108 $2/4,000$ 9198,000 270 3108 $-$ 9200,000 270 32 $366,000$ 11152,000 320 $326,000$ 12 $74,000$ 300 $326,000$ 13 $64,000$ 300 $326,000$ 14 $178,000$ 300 $326,000$ 15 $178,000$ 300 $326,000$ 16 $178,000$ 300 270 17 $62,000$ 300 270 17 $125,000$ 300 270 17 $125,000$ 300 270 17 $125,000$ 300 270 17 $125,000$ 300 270 16 $125,000$ 300 270 17 $125,000$ 320 $270,000$ 16 $125,000$ 320 $270,000$ 17 $125,000$ 320 44 150,000 340 4 $172,000$ 21 $92,000$ 340 4 $270,000$		
8 198,000 270 8 10 82,000 270 300 32 366,000 11 152,000 300 32 366,000 366,000 12 74,000 300 32 8 134,000 12 74,000 300 32 8 105,000 13 64,000 300 256 260,000 32 14 178,000 300 256 260,000 344 16 284,000 300 32 184,000 314,000 16 284,000 300 32 270,000 32 270,000 17 64,000 300 26 4 270,000 310,000 17 156,000 340 4 250,000 270,000 18 198,000 340 4 250,000 270,000 19 198,000 340 4 250,000 250,000 19 100 4	0/1	4
9200,0002701281082,000300303211152,00030034081274,0003003213 $64,000$ 3003214178,0003003215 $64,000$ 3003216 270 32 $184,000$ 17 $62,000$ 300 270 16 $284,000$ 300 270 17 $178,000$ 300 270 16 $284,000$ 300 270 17 $178,000$ 300 270 18 $178,000$ 300 270 16 $284,000$ 300 $270,000$ 17 $128,000$ 300 $270,000$ 17 $128,000$ 300 64 18 $198,000$ 190 64 19 $64,000$ 64 $428,000$ 20 190 64 44 21 $92,000$ 340 4 23 $116,000$ 270 000 240 64 4 $250,000$ 270 000 270 000 21 $92,000$ $92,000$ $92,000$	N/N	ł
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	N/N	I
11 $152,000$ 340 8 $134,000$ 12 $74,000$ 300 300 300 8 $106,000$ 13 $64,000$ 300 3256 $260,000$ $178,000$ 15 $64,000$ $178,000$ 322 $174,000$ 16 $2284,000$ 320 322 $174,000$ 17 $125,000$ 300 32 $270,000$ 17 $125,000$ 300 8 $310,000$ 17 $155,000$ 340 64 44 20 $198,000$ 340 64 $116,000$ 19 000 270 000 $270,000$ 19 000 270 000 $270,000$ 20 $172,000$ $270,000$ $270,000$ 21 $92,000$ 270 64 $1122,000$ 22 $270,000$ 270 $270,000$ 23 $172,000$ 270 $270,000$	500	4
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	285 .	2
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	600	ø
14 178,000 270 32 184,000 15 62,000 140 32 174,000 17 284,000 300 32 270,000 17 155,000 300 32 270,000 18 310,000 340 64 116,000 19 64,000 340 64 116,000 20 198,000 340 4 250,000 20 270 64 116,000 250,000 20 200 270 4 250,000	210	4
$ \begin{bmatrix} 15 \\ 62,000 \\ 174,000 \\ 174,000 \\ 300 \\ 300 \\ 18 \\ 64,000 \\ 540 \\ 64 \\ 116,000 \\ 340 \\ 190 \\ 190 \\ 20 \\ 190 \\ 270 \\ 21 \\ 92,000 \\ 270 \\ 21 \\ 172,000 \\ 270 \\ 22 \\ 172,000 \\ 270 \\ 20 \\ 172,000 \\ 270 \\ 20 \\ 172,000 \\ 270 \\ 20 \\ 172,000 \\ 21 \\ 20 \\ 20 \\ 20 \\ 20 \\ 20 \\ 20 \\$	270	64
16 284,000 300 300 17 155,000 300 8 310,000 18 64,000 540 64 116,000 19 198,000 340 4 250,000 20 150,000 340 4 172,000 21 92,000 270 4 172,000	150	
17 155,000 300 8 310,000 18 64,000 540 64 116,000 19 198,000 190 8 428,000 20 150,000 340 4 250,000 21 92,000 270 4 172,000	300	4
18 64,000 540 64 116,000 19 198,000 190 8 428,000 20 150,000 340 4 250,000 21 92,000 270 4 172,000	340	ω
19 198,000 190 8 428,000 20 150,000 340 4 250,000 21 92,000 270 4 172,000	300	32
20 150,000 340 4 250,000 21 92,000 270 4 172,000	220	64
21 92,000 270 4 172,000	300	4
	300	œ
22 240,000 540 Z 1 210,000	250	2
	V/N	I
	150	16
	270	ч
	480	2
26 1 108,000 200 200 2	001	I

.

٠.

 •

.

APPENDIX B

Patient No.	Hemolytic Compleme	ent - Choo unita per an
	Admission	Convalescence
1 2 3 4 5 6 7 8 9 10	<10 <10 320 3840 240 20 320 120 240 1280 1280	N/A 480 240 <10 320 <10 <10 ×10 N/A N/A 960 1280

 \bigcirc

O

1

Table II. Complement Levels in Plague

APPENDIX C

	Admi	ssion	Conval	escence
Patient No.	Per Cont Eosinophils	Eosinophils/	Per Cent Eosinophils	Eosinophils/ mum ³
1	0	0	12	1188
2	0	0	12	1260
2	0	0	6	312
5	Ő	0	32	3424
4	2	342	1	77
5	2	0	7	368
6	0	440	6	366
7	2	440	0	0
8	0	0	0	0
9	. 0	0	0	1110
10	0	0	13	1110
11	2	258	10	915
12	1	204	10	880
12	1	226	4 .	572
1.5		0	13	780
14	10	072	40	2900
15	81	212	5	333
16	0	U .	14	810
17	9	918	14	019

O

Table	III.	Eosinophilia	in	Convalescent	: P.	lague
-------	------	--------------	----	--------------	------	-------



Table IV. Coagulation Data in Typhoid Fever

I 1

	Admission			County Press	
		Pilheinen		COUVALOSCENCE	
Platelets per mm ³	Fibrinogen mg per 100 ml	Products, Titer	Platelets	Fibrinogen me per 100 ml	Fibrinogen Degradation
					Itonners, litter
176,000	130	32			
11 000	100	**		•	
		80	14.000	300	c
48,000	480	a			0
46.000	and a		34,000	600	8
28 000		0	460,000	105	16
	DOT	80	240.000	end.	2
000 00	230	16		000	20
08.000	285	-	2/0,000	150	00
58,000		*	266,000	600	4
000 82	000	64	176,000	270	a
000.00	160	16	196 000		0
82.000	270		000 000	300	4
62 000		70		1	
	200	4	298,000	200	a

APPENDIX E

Q

Table V. Tube Dilution Susceptibilities, Phage-Types, and Mating Studies in <u>S. typhi</u> Isolates

Minimum Inhibitory Concentration

ug per ml

1	Resistance Transferred	None	C, T, Su, S	C, T, Su, S	C, T, Su, S
	V1-phage Type	E7, atypical	E7, atyp_cal	Degraded Vi	Untypable
	Streptomycin	125	250	500	250
	Sulfadiazine	25,000	25,000	25,000	> 25,000
m rad Sd	Tetracycline	250	125	125	125
	Chloramphenicol	250	. 250	250	200

105* 104* 103* 102* 101* 100* 99. 98* 9 10 11 12 13 14 15 16 17 18 19 20 21 123456 7 8 HOSPITAL DAY BACTRIM 4 TABS CO CHLORAMPHENICOL 1.5 GM CD PO STREPTOMYCIN IGM OD IM ANTIBIOTICS

Q1 -

Figure 1. Highest daily rectal temperatures in degrees Fahrenheit during hospital course of Case A.

LITERATURE CITED.

- Velimirovic, D. Plague in South-East Asia. A Brief Historical Summary and Present Geographical Distribution. Trans. Roy. Soc. Trop. Med. Hyg. 66:479, 1972.
- Rust, J.H., Cavanaugh, D.C., Kadis, S., and Ajl. Plague Toxin. Its Effect in vitro and in vivo. Science 142:408, 1963.
- Finegold, M.J. Pathogenesis of Plague. A Review of Plague Deaths in the U.S. During the Last Decade. Am. J. Med. <u>45</u>:549, 1968.
- Butler, T. A Clinical Study of Bubonic Plague. Observations of the 1970 Vietnam Epidemic with Emphasis on Coagulation Studies, Skin Histology and Electrocardiograms. Am. J. Ned. <u>53</u>:268, 1972.
- 5. Walker, R.V. Comparative Pathophysiology of Plague Endotoxin in Mice, Guinea Pigs, and Monkeys. J. Inf. Dis. <u>118</u>:188, 1968.
- Albizio, J.M., and Surgalla, M.J. Isolation and Biological Characterization of Pasteurella Pestis Endotoxin. Inf. and Imm. 2:229, 1970.
- Ratnoff, O.D., and Menzie, C. A New Method for the Determination of Fibrinogen in Small Samples of Plasma. J. Lab. Clin. Med. <u>37</u>:316, 1951.
- Merskey, C., Kleiner, G.J., and Johnson, A.J. Quantitative Estimation of Split Products of Fibrogen in Human Serum, Relation to Diagnosis and Treatment. Blood <u>28</u>:1, 1966.
- 9. Townes, A.S. Complement Levels in Disease. Johns Hopkins Med. J. 120:337, 1967.
- Levin, J., Poore, T.E., Young, N.S., Margolis, S., Zauber, N.P., Townes, A.S., and Bell, W.R. Gram-negative Sepsis: Detection of Endotoxemia with the Limulus Test. Ann. Int. Med. <u>76</u>:1, 1972.
- 11. McCabe, W.R. Serum Complement Levels in Bacteremia Due to Gramnegative Organisms. N. Eng. J. Med. 288:21, 1973.
- 12. Wintrobe, M.M. Clinical Hematology,6th Ed. Lea and Febiger, Philadelphia, p. 273, 1967.

Х,

- 13. Vasquez, V., Calderon, E., and Rodriguez, R.S. Letter to Editor. New Engl. J. Med. <u>286</u>:1220, 1972.
- 14. Chi, H.K., Ruc, T.M., and Phat, V.N. Sur les cas fievre typhoide a salmonella resistent sulfamethoxazole-trimethoprim et a ampicillin. Acta Medica Vietnamica <u>18</u>:85, 1973.
- Robertson, R.P., Wahab, M.F.A., and Raasch, F.O. Evaluation of Chloramphenicol and Ampicillin in Salmonella Enteric Fever. New Engl. J. Med. 278:171, 1968.
- Geddes, A.M., and Goodal, J.A.D. Letter to the Editor. Brit. Med. J. <u>3</u>:525, 1972.
- Scragg, J.N., and Rubidge, C.J. Trimethoprim and Sulfamethoxazole in Typhoid Fever in Children. Brit. Med. J. <u>3</u>:738, 1971.
- Anderson, E. S., and Smith, H. R. Chlormaphenicol Resistance in the Typhoid Bacillus. Brit. Med. J. <u>2</u>:647-650, 1972.
- Thorne, G. M., Farrar, W. E., Jr. Genetic properties of R factors associated with epidemic strains of <u>Shigella dysenteriae</u> Type I from Central America and <u>Salmonella typhi</u> from Mexico. J. I. D. <u>128</u>:132-136, 1973.
- Gangarosa, E. J., Bennett, J. V., Wyatt, C., Pierce, P. E., Olarte, J., Hernandes, P. M., Vazquez, V., and Bessudo, M. D. An Epidemic-associated Episome? 126:215-216, 1972. J. Inf. Dis.
- Overturf, G., Marton, K. I., and Mathies, A. W. Antibiotic resistance in typhoid fever. New Engl. J. Med. <u>289</u>:463-465, 1973.

PUBLICATIONS.

XI.

- Butler, T., Bell, W. R., Linh, N. N., Tiep, N. D., Arnold, K. <u>Yersinia pestis infection in Vietnam.</u> I. Clinical and hematologic aspects. J. Infect. Dis. <u>129</u> (Suppl.) S78-S84, 1974.
- Butler, T., Linh, N. N., Arnold, K., Pollack, M. Chloramphenicolresistance typhoid fever in Vietnam associated with R factor. Lancet 2:983-985, 1973.

Area